Amplifica Begins Trial For AMP-303
On June 28, 2023, Amplifica Holdings Group announced the initiation of a clinical trial for one of its lead candidate molecules from the study of hairy moles.
Amplifica’s AMP-303 has officially entered a clinical trial. According to a news release on the company’s website and美通社, the first patient was dosed in a multicenter, randomized, double blinded and placebo-controlled study on June 27, 2023. There will be three subject groups within the trial: “subjects with recent onset of hair loss (defined as a history of hair loss of ~3 to 5 years), subjects with established hair loss (defined as a history of hair loss > 10 years); and subjects who have undergone a hair transplant procedure.”This innovative trial design will reveal some new insights into how hair loss drugs can impact hair transplant procedures.
What’s important to take note of, is that the molecule osteopontin, which is a part of the hairy mole-hair growth phenomenon and was recently discussedin the news,was identified as AMP-203 on Amplifica’s website. The compound announced today to enter clinical trials is AMP-303, a distinct compound. Also, SCUBE3 was previously announced on Amplifica’s website asAMP-601.Therefore, it’s possible that AMP-303 could involve CD44, or be a completely different compound which has not been previously discussed.
Amplifica expects this study to be completed in the first quarter of 2024.